These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 33516829)
1. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer. Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829 [TBL] [Abstract][Full Text] [Related]
2. Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. Akin-Akintayo OO; Jani AB; Odewole O; Tade FI; Nieh PT; Master VA; Bellamy LM; Halkar RK; Zhang C; Chen Z; Goodman MM; Schuster DM Clin Nucl Med; 2017 Jan; 42(1):e22-e28. PubMed ID: 27749412 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for Kim EH; Siegel BA; Teoh EJ; Andriole GL; Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848 [TBL] [Abstract][Full Text] [Related]
9. Utility of Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513 [No Abstract] [Full Text] [Related]
10. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198 [No Abstract] [Full Text] [Related]
11. The use of Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411 [TBL] [Abstract][Full Text] [Related]
12. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562 [TBL] [Abstract][Full Text] [Related]
13. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure? Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322 [TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495 [TBL] [Abstract][Full Text] [Related]
16. Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy. Payne H; Bomanji J; Bottomley D; Scarsbrook AF; Teoh EJ; Nucl Med Commun; 2022 Feb; 43(2):201-211. PubMed ID: 34669678 [TBL] [Abstract][Full Text] [Related]